These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22191565)

  • 1. Gender-dependent levels of hyaluronic acid in cerebrospinal fluid of patients with neurodegenerative dementia.
    Nielsen HM; Palmqvist S; Minthon L; Londos E; Wennström M
    Curr Alzheimer Res; 2012 Mar; 9(3):257-66. PubMed ID: 22191565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
    Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
    Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
    Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
    J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered CSF orexin and α-synuclein levels in dementia patients.
    Wennström M; Londos E; Minthon L; Nielsen HM
    J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies.
    Nielsen HM; Minthon L; Londos E; Blennow K; Miranda E; Perez J; Crowther DC; Lomas DA; Janciauskiene SM
    Neurology; 2007 Oct; 69(16):1569-79. PubMed ID: 17761554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies.
    Lemstra AW; de Beer MH; Teunissen CE; Schreuder C; Scheltens P; van der Flier WM; Sikkes SA
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):113-118. PubMed ID: 27794030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia.
    Nägga K; Hansson O; van Westen D; Minthon L; Wennström M
    J Alzheimers Dis; 2014; 42(4):1435-41. PubMed ID: 25024336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M; Surova Y; Hall S; Nilsson C; Minthon L; Hansson O; Nielsen HM
    PLoS One; 2015; 10(8):e0135458. PubMed ID: 26270969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study.
    Wada-Isoe K; Kitayama M; Nakaso K; Nakashima K
    J Neurol Sci; 2007 Sep; 260(1-2):33-7. PubMed ID: 17459416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
    Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
    Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.